A novel membrane-acting immunotoxin, the immunolysin, with therapeutic potential.
Drobniewski
F A
FA
Drug Targeting Laboratory, ICRF Laboratories, Lincolns Inn Fields, London, UK.
Watson
G J
GJ
Wawrzynczak
E J
EJ
Alouf
J E
JE
Thorpe
P E
PE
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D001427:Bacterial Toxins / Q000494:pharmacology* / Q000627:therapeutic use; D002460:Cell Line; D003016:Clostridium perfringens; D003602:Cytotoxicity, Immunologic; D006460:Hemolysin Proteins / Q000494:pharmacology* / Q000627:therapeutic use; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D000922:Immunotoxins / Q000494:pharmacology* / Q000627:therapeutic use; D066298:In Vitro Techniques; D011817:Rabbits
D000911:Antibodies, Monoclonal; D001427:Bacterial Toxins; D006460:Hemolysin Proteins; D000922:Immunotoxins; C020452:Clostridium perfringens theta-toxin